NMVr, due to the ability of ritonavir to inhibit CYP3A4, has an increased risk of drug–drug interactions leading to neuropsychiatric adverse events such as anxiety, insomnia, and cognitive dysfunction [16,17]. The gene discussed is CYP3A4; the disease is Anxiety.